$599

Virta Health Raises $65M in Series D Funding Round

Virta Health announced it raised $65M in a Series D funding round led by Sequoia Capital Global Equities and Caffeinated Capital which values Virta Health at >$1.1B. For context, Virta offers non-pharmaceutical coaching and lifestyle intervention program for chronic metabolic conditions, including T2DM, with the goal of improving patient health and reducing the need for some medications. Below, FENIX provides thoughts on Virta’s funding and valuation in the context of the recent Livongo/Teladoc merger as well as brief thoughts on the Virta value proposition.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.